The FDA suggests a meeting about Rezolute's drug for a rare blood sugar problem, even though it didn't hit all its goals.

RZLT · Rezolute Inc.

The AI's read

The recommendation gives Rezolute a chance to discuss a future application, but it does not promise approval. The sunRIZE study missed its main and key secondary goals. Other readings and ongoing extension results offer encouraging signs, but do not erase those misses. The FDA said approval still depends on a full review, so the news leaves the company’s outlook unchanged.